Article
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
The pharmacogenomics journal - 1 Jan 2002
Shields D C, Fitzgerald A P, O'Neill P A, Muckian C, Kenny D, Moran B, Cannon C P, Byrne C E, Fitzgerald D J
Abstract excerpt
Genetic variants are risk factors for coronary disease, but their role in recurrent events and in response to treatment is less clear. We genotyped genetic variants implicated in primary coronary disease in 924 Caucasians with acute coronary syndromes participating in the OPUS-TIMI16 trial of the GPIIb/IIIa antagonist orbofiban. These were the platelet glycoprotein (GP) receptors GPIIIa, GPIa, GPIbalpha; platelet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.